

ASX RELEASE

VolparaDensity selected for inclusion in latest Tyrer-Cuzick Breast Cancer Risk Assessment Tool

Widely recognised by clinicians and payors worldwide, the Tyrer-Cuzick Risk Assessment Tool now includes breast density alongside family history and genetic factors to aid decision-making process regarding breast cancer screening.

"This is a major validation of Volpara's technology. It is the only commercial density score that has been selected for inclusion into the Tool,"
Dr Ralph Highnam, CEO of Volpara Health Technologies.

Wellington, NZ, 14th November 2016: Volpara Health Technologies ("Volpara"; ASX:VHT), a digital health company focused on early detection of breast cancer by improving quality of screening, has today announced that breast density measurements generated by its Volpara™ Density software have been incorporated into the latest version of the Tyrer-Cuzick Breast Cancer Risk Assessment Tool. Despite being recognised as a major independent risk factor for cancer, this is the first time breast density has been included in a major, widely accepted breast cancer risk model.

"Multiple studies have demonstrated that mammographic density is a strong breast cancer risk factor. After extensive independent testing on multiple data sets, we are pleased to now incorporate volumetric breast density percentages from VolparaDensity as one method of adding breast density into our risk assessment tool. VolparaDensity has strong predictive value, which we believe will help identify high-risk women and guide clinical decisions about adjunctive screening options based on their specific risk factors," said **Jack Cuzick, PhD, FRS, John Snow Professor of Epidemiology, Director, Wolfson Institute of Preventive Medicine, Queen Mary University of London.**

The Tyrer-Cuzick Risk Assessment Tool informs doctors of a woman's risk of developing breast cancer and helps them make decisions about genetic testing and supplemental breast cancer screening. The Tyrer-Cuzick tool incorporates family history, hormonal factors, benign disease, risk factors such as age and body mass index, and genetic factors (including BRCA) into a single statistical model. It estimates the likelihood of a woman developing breast cancer within 10 years of her current age and over the course of her lifetime. Independent clinical studies have shown the Tyrer-Cuzick model to be one of the most consistently accurate when compared with other available risk assessment models.

The model will now include a measure of breast density—making it the first widely recognized breast cancer risk assessment tool to do so. VolparaDensity is the only software-based breast density measurement method to be selected for use with the model, which also accepts visual assessment estimations. The Tyrer-Cuzick tool calibrates the risk according to the breast density measurement method used.

*"The tool will also be a major driver of awareness of breast density as a risk factor for developing cancer, as well as making cancer harder to detect," said **Dr Ralph Highnam, CEO of Volpara Health Technologies**.*

"The Tyrer-Cuzick tool is widely accepted by insurers and payors in the US, and is used to determine whether a woman qualifies for genetic testing or other screening techniques, such as MRI or ultrasound. If clinicians can objectively justify additional screening, and increase their ability to detect cancer earlier, it supports the case for the return of investment on VolparaDensity," Dr Highnam added.

VolparaDensity is part of Volpara's suite of software solutions used to improve the quality of breast cancer screening. It is cleared by the FDA, Health Canada and the TGA, and is CE marked. More than 10 million women have had their breast density analysed using VolparaDensity.

For further information, please contact:

Ralph Highnam, CEO
Volpara Health Technologies
ralph.highnam@volparasolutions.com
t: +64 21 149 0541

Kyahn Williamson
WE Buchan
kwilliamson@buchanwe.com.au
t: +61 3 9866 4722

About Volpara Health Technologies Limited (ASX: VHT)

Founded in 2009 from research originally conducted at Oxford University, VHT is based in Wellington, New Zealand and facilitates the early detection of breast cancer through its digital health solutions to enable personalised, high-quality breast cancer screening based on objective measurements of breast density.

VHT has a number of patents, trademarks and regulatory clearances, including FDA and CE, supporting its technology and services. It launched its cloud-based **VolparaEnterprise™** solution, which incorporates breast density screening with a range of automated quality control features focused on improving quality and productivity, in July 2016.

VHT listed on ASX in April 2016 after a \$10m IPO and has customers and/or research projects in 35 countries.

www.volparasolutions.com